Interested in new trials?
Get alerts for new trials in your area by subscribing now
An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection
What is postpartum depression?
Postpartum depression is a major depressive episode that begins during pregnancy or in the year after childbirth, most often within the first weeks or months. It is different from the baby blues, the tearfulness and mood swings that affect most new mothers in the first two weeks and pass on their own. Postpartum depression lasts longer, usually at least two weeks, and is deeper: persistent sadness or emptiness, loss of interest, severe anxiety or panic, trouble bonding with the baby, guilt, changes in sleep and appetite beyond what a newborn causes, and sometimes thoughts of harming oneself or the baby. Those last thoughts are frightening and common, and they are a reason to seek help immediately, not a sign of being a bad parent. Fathers and partners can develop it too, with estimates around 1 in 10.
The causes are a mix of the steep hormonal drop after delivery, sleep deprivation, a history of depression or anxiety, lack of support, and stressful circumstances. Without treatment it can last months or longer and affects the child's development as well as the mother. Treatment works: psychotherapy, standard antidepressants, and support all help, and the two newer medicines act on a different brain system than SSRIs. Brexanolone, approved in 2019, is a 60 hour hospital infusion; zuranolone is a two week course of pills taken at home, approved in 2023 after trials in women with severe postpartum depression showed significant improvement by day 15 that lasted after the course ended. Both are neurosteroids, a new class of psychiatric medicine, and trials are now testing whether an oral version of brexanolone, ketamine, and rapid magnetic stimulation can help more people faster.
Types of postpartum depression clinical trials
New medicine trials. An oral form of brexanolone in Phase 3, ketamine based approaches, and long term follow up of people treated with zuranolone.
Brain stimulation trials. Accelerated transcranial magnetic stimulation, delivering a full course in five days, tested in women who cannot wait weeks for relief.
Therapy and coaching trials. Psychotherapy adapted to the postpartum period, parent coaching, and programs delivered by phone or video for families far from specialists.
Prevention trials. Studies in pregnant women at high risk, testing whether support or treatment during pregnancy prevents depression after birth.
Sleep and circadian studies. Interventions targeting the disrupted sleep of new parenthood as a driver of mood.
Infant and family outcome studies. Research on how maternal mood affects breastfeeding, bonding, and child development, and how treatment changes that.
New to research? Read how informed consent works.
Who can participate in postpartum depression clinical trials?
Most treatment trials enroll women who gave birth within the past 6 to 12 months and meet criteria for a major depressive episode on a structured interview and a severity scale, often with onset in late pregnancy or the first weeks after delivery. Medicine trials usually require that you are not breastfeeding or are willing to pause, since the study drug may pass into milk, and some allow a stable existing antidepressant. Brain stimulation trials have safety rules such as no seizures or metal implants. Prevention trials enroll pregnant women with a history of depression. Therapy and coaching studies have wider doors and often include partners. Some trials accept participants from age 15. Eligibility always varies by study; our guide covers eligibility criteria.
How long does postpartum depression last?
Without treatment it can last many months, and for some women more than a year; with treatment most improve within weeks to a few months. The newer medicines, zuranolone and brexanolone, act within days, and trials are testing other fast approaches. Anything lasting beyond two weeks after birth is not the baby blues and deserves care.
Timing and severity, and why they matter for trials
Baby blues. Mood swings and tearfulness in the first two weeks that resolve on their own. Not a trial target, but worth knowing so a longer episode is not dismissed.
Mild to moderate postpartum depression. Symptoms for two weeks or more that interfere with daily life. Therapy, coaching, and digital trials often enroll here.
Severe postpartum depression. High scores on a depression scale, often with inability to function or thoughts of self harm. Medicine and brain stimulation trials usually require this severity, and it needs urgent clinical care alongside any study.
Postpartum psychosis. Rare and an emergency: confusion, hallucinations, or delusions after birth. Not studied in these trials and requires immediate hospital care.
Study listings state the time since delivery and the severity score required; the clinician who screens you measures it.
How to enroll in a postpartum depression clinical trial
Identify your trial. Use the filters. Titles say "postpartum" or "perinatal" and name the approach: medicine, stimulation, therapy, or coaching.
Select your preferred location. Enter your city or state. Medicine and stimulation trials need in person visits; many therapy and coaching studies run by video.
Explore study details. Click "Learn More" for how long since delivery, severity required, and breastfeeding rules.
Complete the health profile. Click "Get started" to begin the 5-step application. Have three things ready: your delivery date and when symptoms began, any treatment you have started, and whether you are breastfeeding. A partner can help complete the application.
Submit the application. A clinical trial coordinator reviews it and contacts you. Nothing is decided until informed consent, and participation is voluntary at every step. If you have thoughts of harming yourself or your baby, seek help now; a trial is not emergency care.